<DOC>
	<DOCNO>NCT01813799</DOCNO>
	<brief_summary>This Phase II dose-ranging study evaluate effectiveness safety DA-9801 treatment pain associate diabetic neuropathy . Subjects receive either 300mg , 600mg , 900mg placebo , three time daily eight week . During treatment , pain score Likert numerical rating scale , Patient Global Impression Improvement ( PGI-I ) Change Clinical Global Impression ( CGI ) access evaluate effectiveness .</brief_summary>
	<brief_title>Study DA-9801 Treat Diabetic Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>age 20 ~ 70 Type I Type II Diabetes HbA1c â‰¤11 % Patients diabetic neuropathic pain least 3 month Patients corresponding average pain level 4 point 24 hour evaluate 11point Likert scale neuropathic pain due cause another strong pain neuropathic pain abnormal blood pressure , weight , ALT/AST , Serum creatinine positive reaction HIV , HBV , HCV experience suicide try Mental Illness Medical History BDI ( Beck Depression Inventory ) grade exceed 21 point chronic alcohol abuse history</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Diabetic Neuropathies</keyword>
</DOC>